Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) underlie the pathogenesis and chemoresistance of ∼30% of all human tumors, yet the development of high-affinity inhibitors that target the broad range of KRAS mutants remains a formidable challenge. Here, we report the development and validation of stabilized alpha helices of son of sevenless 1 (SAH-SOS1) as prototype therapeutics that directly inhibit wild-type and mutant forms of KRAS. SAH-SOS1 peptides bound in a sequence-specific manner to KRAS and its mutants, and dose-responsively blocked nucleotide association. Importantly, this functional binding activity correlated with SAH-SOS1 cytotoxicity in cancer cells expressing wild-type or mutant forms of KRAS. The mechanism of action of SAH-SOS1 peptides was demonstrated by sequencespecific down-regulation of the ERK-MAP kinase phosphosignaling cascade in KRAS-driven cancer cells and in a Drosophila melanogaster model of Ras85D V12 activation. These studies provide evidence for the potential utility of SAH-SOS1 peptides in neutralizing oncogenic KRAS in human cancer.
Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) underlie the pathogenesis and chemoresistance of ∼30% of all human tumors, yet the development of high-affinity inhibitors that target the broad range of KRAS mutants remains a formidable challenge. Here, we report the development and validation of stabilized alpha helices of son of sevenless 1 (SAH-SOS1) as prototype therapeutics that directly inhibit wild-type and mutant forms of KRAS. SAH-SOS1 peptides bound in a sequence-specific manner to KRAS and its mutants, and dose-responsively blocked nucleotide association. Importantly, this functional binding activity correlated with SAH-SOS1 cytotoxicity in cancer cells expressing wild-type or mutant forms of KRAS. The mechanism of action of SAH-SOS1 peptides was demonstrated by sequencespecific down-regulation of the ERK-MAP kinase phosphosignaling cascade in KRAS-driven cancer cells and in a Drosophila melanogaster model of Ras85D V12 activation. These studies provide evidence for the potential utility of SAH-SOS1 peptides in neutralizing oncogenic KRAS in human cancer.
AS signaling is a critical control point for a host of cellular functions ranging from cellular survival and proliferation to cellular endocytosis and motility (1) . The on or off state of RAS is dictated by nucleotide exchange. GTP-bound RAS is the activated form that engages its downstream effectors with high avidity. The endogenous GTPase activity of RAS hydrolyzes GTP to GDP and inactivates signaling. This biochemical process is further regulated by GTPase-activating proteins (GAPs) that impair RAS signaling through increasing endogenous GTPase activity and guanine-nucleotide exchange factors (GEFs) that enhance RAS signaling by facilitating GDP release and, thus, GTP association. Given the central roles of RAS in cellular growth and metabolism, it is not surprising that cancer cells usurp its prosurvival activities to achieve immortality.
Activating mutations in KRAS represent the most frequent oncogenic driving force among the RAS homologs K-, N-, and H-RAS, and are associated with poor prognosis and chemoresistance (2) . KRAS mutations are present in ∼30% of human tumors and at even higher frequencies in cancers of the pancreas, lung, thyroid gland, colon, and liver. For example, in pancreatic ductal adenocarcinomas (PDAC) that carry a 5-y survival rate of less than 5%, activating KRAS mutations are present in more than 90% of tumors (3) . Thus, therapeutic inhibition of RAS is among the highest priority goals of the cancer field. Because oncogenic forms of KRAS typically harbor single-point mutants that stabilize its active GTP-bound form, a host of recent small molecule and peptide development efforts have been aimed at disarming this pathologic biochemical state. The extremely high affinity of KRAS for its GTP substrate has hampered the development of competitive GTP inhibitors. However, a GDP mimetic that covalently modifies the mutant cysteine of KRAS G12C represents a promising approach to plugging the nucleotide-binding site (4) . The prototype compound SML-10-70-1 demonstrated antiproliferative effects in the 25-50 μM range, although it did not appear to discriminate between KRAS-dependent and KRAS-independent growth (4). An elegant screening strategy based on covalent engagement of the G12C thiol identified promising inhibitors that target a new allosteric site adjacent to the nucleotide exchange region (5). These compounds not only switched the nucleotide-binding preference of KRAS G12C to GDP over GTP (5) , favoring the inactive state, but may also diminish effector interactions, a distinct and complementary RAS-inhibitory activity exploited by another series of small molecules recently identified by in silico screening (6) . Compounds that emerged from these molecular tethering and in silico strategies have demonstrated micromolar and submicromolar range antitumor responses in cancer cells driven by KRAS G12C and KRAS G12V, respectively (5, 6) .
Because the KRAS-GDP to KRAS-GTP transition catalyzed by the GEF, son of sevenless 1 (SOS1), represents the ratelimiting step for nucleotide exchange (7, 8) , disrupting the activating SOS1/KRAS protein interaction has also been the focus of drug development efforts (9) . A synthetic peptide incorporating select residues of the SOS1 helical interaction motif and structurally stabilized by hydrogen bond surrogate (HBS) chemistry yielded mid-to high-micromolar binders that inhibited wild-type Ras-ERK phosphosignaling (10) . Two NMR-based fragment screens independently identified small molecules that also bind to KRAS in the mid-to high-micromolar range and disrupted SOS1-mediated RAS activation (11, 12) . However, the effects of these new peptidic and small molecule agents on cancer cell viability were not evaluated (10) (11) (12) . In an interesting twist, a set of recently Significance KRAS is one of the most prevalent and vicious oncogenic proteins, yet no drugs are available to inhibit its pathologic activity in patients. We report that KRAS-targeting stapled peptides, modeled after the native son of sevenless 1 (SOS1) helical domain, engage wild-type and clinically relevant KRAS mutant proteins with nanomolar affinity. To our knowledge, these compounds represent the highest affinity and broadest spectrum binders of KRAS mutants reported to date. The stapled peptides disrupt the SOS1/KRAS protein interaction and directly inhibit nucleotide association to wild-type and mutant KRAS proteins. We correlate functional binding activity with SAH-SOS1 cytotoxicity across a 13-member panel of KRAS-driven cancer cells and demonstrate sequence-and dose-dependent inhibition of the ERK-MAP kinase phosphosignaling cascade downstream of KRAS in vitro and in vivo.
described small molecule hits engaged the RAS-SOS1-RAS ternary complex at a unique hydrophobic pocket, activated nucleotide exchange, and perturbed phosphosignaling downstream of RAS (13) . Finally, a combinatorial screening approach identified several cyclic peptides with submicromolar RAS-binding activity, but no cellular activity was observed (14) . Despite the recent progress in developing small molecules and synthetic peptides to directly target RAS or RAS-SOS1, high-affinity binders with promising cellular activity across the broad spectrum of wild-type and mutant KRAS-driven cancers have remained out of reach. Thus, there is a pressing need for next-generation agents to target and disarm KRAS in human cancer cells.
We have previously generated "stapled peptides" modeled after key α-helical interaction domains to disrupt oncogenic protein interactions of the BCL-2 family, p53, β-catenin, and EZH2 pathways (15) (16) (17) (18) . By sampling alternative staple positions, interrogating cellular uptake, and correlating biochemical function with antitumor activity and mechanism of action, we have generated lead compounds that form the basis for therapeutic development (16, 17, 19, 20) . Here, we report the application of all-hydrocarbon stapling to recapitulate the native primary sequence and secondary structure of the RAS-interacting α-helix of SOS1. Our goal was to develop a direct inhibitor that binds the diversity of KRAS mutant forms, impairs nucleotide exchange and, importantly, broadly kills KRAS-mutant cancer cells in a sequence-specific manner by deactivating its downstream phosphosignaling cascade.
Results

SAH-SOS1 Peptides Bind to Wild-Type and Mutant KRAS with Nanomolar
Affinity. The crystal structure of the complex between the SOS1 catalytic domain and KRAS (PDB ID code: 1NVU) (21) demonstrated direct contact between a SOS1 α-helix (cyan) and KRAS, implicating this interface in catalyzing nucleotide exchange (Fig.  1A) . Using the primary sequence of this SOS1 α-helix (amino acids 929-944), we generated a series of stabilized alpha helices of SOS1 (SAH-SOS1) peptides bearing alternatively positioned i, i+4 staples ( Fig. 1A and Fig. S1A ). The resultant SAH-SOS1 a-d peptides were then screened by fluorescence polarization (FP) assay for binding activity to recombinant hexahistidine-tagged (His 6 ) KRAS proteins, including wild-type and G12D, G12V, G12C, G12S, and Q61H mutant forms (Fig. S1B) . Whereas SAH-SOS1 peptides a, c, and d demonstrated nanomolar binding activity in the 60-160 nM range, SAH-SOS1 b showed little to no interaction, consistent with the disruptive location of its staple at the KRAS binding interface (Fig. 1A and Fig. S1 ).
We selected SAH-SOS1 a for further development based on its superior binding activity and solubility profile, and also advanced SAH-SOS1 b as an ideal negative control for biochemical and cellular studies. To optimize these constructs for cellular work, we further appended two Arg residues at the N termini to adjust the overall charge of the peptides from −1 to +1, based on our longstanding observation across multiple stapled peptide templates that cellular uptake is enhanced when overall charge is ≥0 (22, 23) . We confirmed the cellular penetrance of these revised constructs (Table S1 and Fig. S2 ), hereafter referred to as SAH-SOS1 A and SAH-SOS1 B (using capital letter subscripts), by confocal microscopy (Fig. S3A) , fluorescence scan of electrophoresed lysates from treated cells (Fig. S3B) , and high-content microscopic imaging analysis (Fig. S4) . We then repeated the FP binding analyses by using our positive and negative control SAH-SOS1 constructs, documenting a 100-to 175-nM binding range for SAH-SOS1 A across the His 6 -KRAS proteins, with no binding activity observed for SAH-SOS1 B (Fig. 1) . As an additional measure of relative binding activity, we demonstrated that SAH-SOS1 A , but not SAH-SOS1 B , disrupted the protein interaction between recombinant GST-KRAS and His 6 -SOS1 proteins in vitro (Fig. S5A) . We confirmed that SAH-SOS1 A was capable of dissociating the protein complex owing to its capacity to directly target KRAS in solution, as demonstrated by streptavidin pulldown of biotinylated SAH-SOS1 A and anti-KRAS Western blot analysis (Fig. S5B) . Thus, we find that insertion of an all-hydrocarbon staple into the native SOS1 sequence (amino acids 929-944) at the noninteracting helical face yields peptidic ligands that bind to KRAS in the nanomolar range, representing at least a two orders of magnitude improvement over the recently published peptide and small molecule inhibitors of the KRAS/SOS1 interface.
SAH-SOS1
A Engages both GDP-KRAS and GTP-KRAS. Because KRAS exists in two distinct conformations depending on its interaction with GDP vs. GTP (24), we next tested whether SAH-SOS1 A engages one or both forms of KRAS. FP analysis using GDPand GTP-loaded, recombinant, wild-type KRAS revealed equivalent SAH-SOS1 A binding affinities (Fig. S6A) , consistent with the capacity of SAH-SOS1 A to engage both forms of KRAS. As an additional measure of direct binding activity, we performed differential scanning fluorimetry by using GDP-and GTP-loaded forms of KRAS in the presence or absence of SAH-SOS1 A or the negative control peptide SAH-SOS1 B . GTP-loaded KRAS demonstrated a lower melting temperature than GDP-loaded KRAS (Fig. S6B ), reflecting the more rigid structure of the GDP-loaded form (and relative inaccessibility of the SYPRO dye until the GDP-loaded form unfolds at the higher temperature). Upon addition of SAH-SOS1 A , both forms of KRAS demonstrate a shift in the melting curve, consistent with a small increase in conformational flexibility from ligand binding. Indeed, the SOS1 interaction is believed to favor the KRAS "open" conformation (21) , and allosteric release of nucleotide can also decrease the structural stability of the KRAS protein (25) . Importantly, the observed changes in KRAS are peptide sequence-specific, as the negative control stapled peptide, SAH-SOS1 B , had no such effect (Fig. S6B ).
To further confirm that SAH-SOS1 A peptide specifically targets KRAS at the SOS1 binding pocket, we performed NMR analysis of GDP-loaded 15 N-KRAS upon incubation with SAH-SOS1 A . We find that the overall fold of KRAS is preserved upon SAH-SOS1 A engagement, and discrete chemical shift changes occur in residues that colocalize at the SOS1-binding site (see below) and the very region of KRAS implicated in conformational opening during SOS1 protein engagement (e.g., H27, F28, V29, R149) ( Fig. 2 A and B) . A calculated model structure derived from docking analyses demonstrated the juxtaposition of SAH-SOS1 A residues with the majority of residues that undergo chemical shift change, such as L6, G15, L56, D57, E63, Y64, R73, T74, and Q99 (Fig. 2C) . Taken together, our biochemical data demonstrate that SAH-SOS1 A directly binds to both GDP-and GTP-loaded forms of KRAS, with the structural analysis implicating the SOS1-binding pocket as the functional site of SAH-SOS1 A interaction.
SAH-SOS1 A Directly Inhibits Nucleotide Association to KRAS. We next sought to determine whether the direct binding of SAH-SOS1 A could independently impact the capacity of KRAS to exchange nucleotide and, in particular, the activating nucleotide association process. The addition of the fluorescent GTP analog, mant-GTP (2′-/3′-O-(N′-methylanthraniloyl)guanosine-5′-O-triphosphate), associated with wild-type His 6 -KRAS in a time-dependent fashion, as demonstrated by the increase in measured fluorescence (Fig. 3A) . As a negative control, we incubated KRAS with mant-GTP and excess unlabeled GTP, which completely blocked mant-GTP association (Fig. 3A) . We then coincubated KRAS with mant-GTP and either SAH-SOS1 A or SAH-SOS1 B . Whereas SAH-SOS1 A dose-responsively inhibited mant-GTP association, SAH-SOS1 B had little to no effect (Fig. 3A) .
To evaluate the functional impact of SAH-SOS1 peptides on the G12D mutant form of KRAS, mant-GDP association was examined because of the slower kinetics of mant-GTP binding in this experimental context. The incubation of His 6 -KRAS G12D with mant-GDP resulted in time-responsive association, which was blocked upon coincubation with excess unlabeled GDP (Fig.  3B) . As above, coincubation of KRAS G12D with mant-GDP and SAH-SOS1 A peptide dose-responsively blocked nucleotide association, whereas SAH-SOS1 B , which does not bind to wildtype or mutant KRAS, had no effect. Thus, we find that engagement of wild-type or KRAS G12D by SAH-SOS1 A independently blocks the capacity of KRAS to engage nucleotides in both a dose-responsive and sequence-dependent fashion.
A Impairs the Viability of KRAS-Mutant Cancer Cells. Whereas micromolar quantities of small molecules and peptides were shown to target the SOS1/KRAS binding region and disrupt nucleotide exchange activity (10) (11) (12) , the effect of these agents on cancer cell viability was not explored. We therefore tested whether our lead SAH-SOS1 A construct, which binds to wild-type and mutant forms of KRAS in the 100-to 175-nM range, could inhibit the viability of pancreatic, colon, and lung cancer cells bearing distinct KRAS mutations. We found that SAH-SOS1 A , but not the negative control peptide SAH-SOS1 B , dose-responsively impaired the viability of cancer cells bearing KRAS G12D (Fig. 4A and Fig.  S7A ), G12C (Fig. S7B) , G12V (Fig. S7C) , G12S (Fig. S7D) , G13D (Fig. S7E) , and Q61H (Fig. S7F ) mutations with IC 50 values in the 5-to 15-μM range. Cancer cells expressing wild-type KRAS, such as HeLa and Colo320-HSR cells, were similarly affected (Fig. S8A) . Importantly, we confirmed that at the doses that SAH-SOS1 A was cytotoxic to cells, the stapled peptide was soluble and monomeric (Fig. S9) .
To further probe the specificity of SAH-SOS1 A activity, we generated five mutant constructs that incorporated, for example, conversions of select hydrophobic residues to charged residues, and hydrophilic residues to hydrophobic residues (Fig. 4B) . We then measured His 6 -KRAS G12D binding activity and cell viability responses in the KRAS G12D-bearing Panc 10.05 cancer line. Strikingly, those SAH-SOS1 A mutant peptides that retained KRAS G12D binding activity (mut1-2) inhibited cell viability, whereas those mutants that lost binding activity (mut3-5) had no effect on cancer cell viability (Fig. 4 C and D) . Thus, we find that SAH-SOS1 A manifests dose-responsive and sequence-specific antitumor activity across a broad spectrum of wild-type and mutant KRAS-expressing cancer cell lines.
SAH-SOS1 A Inhibits Phosphosignaling Downstream of KRAS in Vitro
and in Vivo. To determine whether the observed inhibitory effect of SAH-SOS1 A on cancer cell viability could be linked to negative modulation of KRAS signaling activity, we examined the dose-dependent effects of SAH-SOS1 A treatment on the phosphorylation state of MEK, ERK, and AKT in Panc 10.05 cells exposed to EGF. Whereas SAH-SOS1 A dose-responsively inhibited MEK1/2, ERK1/2, and AKT phosphorylation, SAH-SOS1 B had no effect (Fig. 5A ). An analogous SAH-SOS1 A -specific effect was observed in HeLa cells bearing wild-type KRAS (Fig. S8B) . Importantly, the dosing at which SAH-SOS1 A down-regulated phosphorylation matched the concentrations required to impair cancer cell viability (Figs. 4A and 5A and Fig. S8 ). Finally, we evaluated whether the inhibitory effects of SAH-SOS1 A on KRAS signaling observed in cancer cells could be extended to an in vivo context. For this work, we used an inducible system in Drosophila melanogaster for Ras1, the major Drosophila homolog of N-ras, H-ras, and K-ras genes (26) . In this model, Actin Geneswitch (ActinGS) drives broad and high level tissue expression of a V12-mutant form of RAS85D upon treatment with RU486 (27) . For our first study, we induced RAS85D V12 for 3 d by using 150 μM RU486, which was added directly to the fly food. We then injected vehicle or SAH-SOS1 A directly into the fly abdomens, and 48 h later performed Western blotting for phospho-ERK1/2 on the harvested tissue extracts. SAH-SOS1 A treatment notably decreased the phosphorylation state of ERK1/2 (Fig. 5B) . Next, we added SAH-SOS1 A directly to the fly food, as for RU486, and after 3 d of RAS85D V12 induction, Western blotting for phospho-ERK1/2 and phospho-AKT was performed. We observed near complete suppression of ERK1/2 and AKT phosphorylation at the 100 μM SAH-SOS1 A dosing level (Fig. 5C) . To probe the specificity of the response, we repeated the experiment comparing responses to vehicle, SAH-SOS1 A , and SAH-SOS1 B after 3 and 5 d treatment with RU486 and SAH-SOS1 peptides. In each case, we observed a decrease in ERK1/2 phosphorylation upon SAH-SOS1 A treatment, whereas SAH-SOS1 B had no effect (Fig. S10) . Of note, SAH-SOS1 peptides had no independent effect on the levels of RAS or ERK protein, and no fly toxicity was observed from the treatments. Discussion KRAS is one of the most pervasive pathogenic factors in human cancer but no drugs are available for clinical use to directly bind and block this deadly protein. Over the last few years, there has been a flurry of new reports suggesting that small molecules and peptide prototypes may, in fact, be capable of engaging KRAS to block its GTP binding site, impair nucleotide exchange, tip the equilibrium in favor of the inactive state, and/or block interactions with effectors. Whereas the majority of approaches have achieved proof-of-concept for engagement of RAS or KRAS, and consequent biochemical modulation (albeit at mid-to highmicromolar concentrations), anticancer activity was either not yet explored, not observed, or required dosing levels that would preclude clinical translation. A notable exception are compounds that engage a novel binding pocket beneath the effector binding switch-II region of the G12C mutant form of KRAS. These new agents exhibited submicromolar antiproliferative activity specifically in KRAS G12C-driven cancer cells. Indeed, all of these new strategies hold promise that further iteration and optimization could lead to a breakthrough anti-KRAS agent. In the meantime, continued exploration of chemical space and extension of structural and biochemical studies into the cellular and in vivo realms is required.
Stapled peptides are a relatively new class of structured peptides, designed to mimic bioactive helices yet remedy the traditional shortcomings of peptide therapeutics, namely loss of shape, proteolytic lability, and difficulty accessing intracellular targets. When appropriately designed and optimized, stapled peptides can manifest remarkable structural stability, extracellular and intracellular protease resistance, and the capacity to gain entry to the cell via energy-dependent macropinocytosis (18, 23) . Sampling a series of staple locations along the length of the peptide can yield highaffinity binders and, importantly, negative control compounds based on the replacement of key amino acid residues or steric interference of the staple at the binding interface. Here, we find that SAH-SOS1 A can target the SOS1-binding pocket on KRAS with nanomolar affinity, directly and independently block nucleotide association, impair KRAS-driven cancer cell viability, and exert its effects by on-mechanism blockade of the phosphosignaling cascade downstream of KRAS. Importantly, all of these activities are dose-and sequence-dependent. Using a Drosophila model of induced mutant RAS expression, we find that the effects of SAH-SOS1 A , administered by injection or orally, extend to an in vivo context. Thus, a peptide-stapling approach to targeting the SOS1 regulatory groove on KRAS may be a viable strategy for therapeutic development.
One of the most promising features of our stapled peptide results is the broad spectrum, nanomolar targeting capacity of SAH-SOS1 A across both wild-type and a diversity of KRAS mutant forms. Indeed, SAH-SOS1 peptides are among the highest affinity KRAS binders reported to date, and address the most clinically relevant forms of mutant KRAS, including the G12V, G12D, G12C, G12S, G13D, and Q61H variants. Importantly, the SAH-SOS1 A approach can harness dual biochemical activities, in that it can both disrupt the activating SOS1/KRAS protein interaction, while also independently block nucleotide association as a direct result of its interaction with KRAS. It appears that the SOS1-binding interface provides a platform for SAH-SOS1 A engagement of KRAS irrespective of mutant form, with peptide interaction effectively and uniformly blocking nucleotide association, as exemplified by our biochemical results using recombinant wild-type and G12D-mutant KRAS. Indeed, more than a dozen cancer lines expressing either wild-type or mutant KRAS protein were susceptible to SAH-SOS1 A treatment.
A potential therapeutic window for this treatment strategy may derive from the relative dependency of such cancer cells on KRAS compared with normal cells. Our studies in Drosophila did not reveal toxicity from SAH-SOS1 A -induced down-regulation of RAS-driven phosphosignaling. It is also noteworthy that pancreatic cancer cells have been shown to up-regulate macropinocytosis as a unique means of nutrient loading (28) . Because appropriately designed stapled peptides can achieve cellular penetrance via the same macropinocytotic pathway, preferential uptake of therapeutic peptide by KRAS-driven pancreatic cancer cells may provide a further measure of tissue selectivity. Future directions include further optimizing the potency of prototype SAH-SOS1 peptides by using structure-activity relationships, exploring the therapeutic window for KRAS modulation in vivo by building on the Drosophila results, and advancing lead constructs to preclinical testing in murine models of KRAS-driven cancers.
Methods
Peptide Synthesis and Characterization. Fmoc-based automated peptide synthesis, hydrocarbon stapling by olefin metathesis, and N-terminal derivatization with FITC-β-Ala, acetyl, or Biotin-β-Ala were performed according to our established methods (22) . All peptides were purified by liquid chromotography/ MS to >90% purity and quantified by amino acid analysis (Table S1 and Fig. S2 ).
KRAS Protein Purification.
Recombinant wild-type human KRAS protein (amino acids1-156) and its G12D, G12V, G12S, G12C, and Q61H mutant variants were expressed in Escherichia coli BL21(DE3) as N-terminal hexahistidine-tagged (His 6 ) fusion proteins by using the pET28-MHL expression vector (Addgene plasmid 25153; a gift from C. Arrowsmith, University of Toronto, Toronto). Protein expression was induced with 1 mM IPTG for 4 h at 30°C. Bacterial pellets were resuspended in lysis buffer (20 mM Tris, 250 mM NaCl, pH 7.6), lysed by microfluidization (Microfluidics M-110L), and centrifuged at 45,000 rpm for 1 h at 4°C (Beckman L-90K). The cleared cellular lysates were subjected to Ni affinity resin (Qiagen) chromatography followed by elution with 150 mM imidazole in 50 mM Tris, 250 mM NaCl, pH 7.8. Concentrated eluates were subjected to size exclusion chromatography (GE Life Sciences) at 4°C by using 50 mM Tris, 150 mM NaCl, pH 7.8 buffer conditions, and the corresponding monomeric peaks were collected. Protein concentration was determined by Bradford assay (Bio-Rad) and UV absorbance measurements, and the average value was used. His 6 -tagged KRAS proteins were used in all biochemical experiments unless otherwise indicated.
Fluorescence Polarization Assay. FP assays were performed as described (18) . Briefly, FITC-SAH-SOS1 peptides (15 nM) were incubated with the indicated serial dilution of KRAS wild-type or mutant protein in binding buffer (50 mM Tris, 100 mM NaCl, pH 8.0) until equilibrium was reached (30 min). Fluorescence polarization was measured using a SpectraMax M5 microplate reader (Molecular Devices). EC 50 values were calculated by nonlinear regression analysis of dose-response curves using Prism software (GraphPad).
Nucleotide Loading. Nucleotide loading for FP, differential scanning fluorimetry (DSF), and NMR spectroscopy studies were performed as described (21) . Purified KRAS protein (200 μM) was incubated with 2 mM GDP or GppNp in loading buffer [20 mM Tris·HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 mM DTT] for 1.5 h on ice. Reactions were quenched with 12 mM MgCl 2 and incubated for 30 min on ice. For DSF (SI Methods), the protein was used without further purification, whereas for NMR and FP, excess of the free nucleotides was removed and the buffer exchanged into PBS, 1 mM DTT, 2 mM MgCl 2 using preequilibrated NAP-5 columns (GE Life Sciences).
NMR Spectroscopy. All spectra were collected by using an Agilent Inova 500 MHz system equipped with a triple resonance (H, C, N) 5-mm cold probe. Experiments were performed at 25°C. KRAS was uniformly 15 N isotopically labeled, charged with GDP as described above, and dissolved in phosphate buffer , with the scale factor α taken to be 0.14 (30) . The absence of a bar indicates no chemical shift change, the presence of a proline, or a residue that is overlapped or not assigned. Docking Calculations. The peptide sequence FFGIXLTNXLKTEEGN was built by using Maestro in an idealized α-helical form. The sequence was docked to the target protein by using the HADDOCK webserver default parameters (31, 32) . Chain R of the 1NVU crystal structure (21) was used, with residues L6, G15, H27, F28, V29, L56, D57, E63, Y64, R73, T74, G77, and R149 defined as the active residues. Top-scoring clusters were analyzed visually with Pymol (Schrödinger, LLC).
Nucleotide Association Assay. The association of mant-GTP with wild-type KRAS protein was monitored by fluorescence measurement over time on a Tecan X1000 fluorescence spectrometer (excitation 360 nm, emission 440 nm) (12) . SAH-SOS1 peptides at the indicated amounts were incubated with 1 μM KRAS and 1 μM mant-GTP in buffer containing 25 mM Tris (pH 7.5), 50 mM NaCl, and 1 mM DTT at 25°C. KRAS and mant-GTP alone established the positive control for association, and competition with 200-fold excess unlabeled GTP served as the negative control. The identical association experiment was performed with KRAS G12D except that mant-GDP was used instead, because
